BeStock  
Stocks › Biotechnology › ABUS

Arbutus Biopharma ABUS

US equityMarket cap rank #3471Biotechnology
$4.02 −$0.05 (-1.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.98 -1.00%
Open$4.01
Prev close$4.07
Day range$3.97 – $4.09
Volume2.99M
Market cap$616.24M
P/E (TTM)3.6
Dividend yield–

ABUS Stock News

Headlines matching Arbutus Biopharma or the ABUS ticker, most recent first.

  • Arbutus Biopharma: Arbutus Biopharma Corporation - Broker-To-Broker Settlement/Exercise Considerations Option Symbol: ABUSOCC · 26 Sep 2026 · Direct mention
  • Arbutus Biopharma: Arbutus Biopharma Corporation - Partial Self Tender Offer Option Symbol: ABUSOCC · 28 Aug 2026 · Direct mention
  • Earnings Flash (ABUS) Arbutus Biopharma Posts Q1 EPS $0.87, Vs. FactSet Est of $0.03 Loss NegativeMT Newswires · 13 May 2026 · Direct mention
  • Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Total Revenue $14.1M, Vs. FactSet Est of $13.6MMT Newswires · 23 Mar 2026 · Direct mention
  • Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Loss $0.17 a Share, Vs. FactSet Est of $0.19 Loss NegativeMT Newswires · 23 Mar 2026 · Direct mention
  • ABUS Stock Has Given up Its Prior Gain. Arbutus Biopharma Shares Were Trading Higher After the Company Presented Clinical Trial Data From Its Two HBV Assets. PositiveBenzinga · 7 May 2025 · Direct mention
  • JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5Market news · 31 Mar 2025 · Direct mention
  • Earnings Flash (ABUS) Arbutus Biopharma Corporation Reports Q3 Revenue $529,000, Vs. FactSet Est of $1.3MMT Newswires · 13 Nov 2025 · Direct mention
  • H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5Market news · 21 Jan 2025 · Direct mention
  • Jefferies Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $7 PositiveMarket news · 6 Sep 2024 · Direct mention
  • Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4Market news · 2 Aug 2024 · Direct mention
  • JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5 PositiveMarket news · 2 Aug 2024 · Direct mention
  • Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $4.5 PositiveMarket news · 7 Nov 2024 · Direct mention
  • Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5 PositiveMarket news · 20 Nov 2024 · Direct mention
  • H.C. Wainwright Keeps Their Buy Rating on Arbutus Biopharma (ABUS)TipRanks · 12 Sep 2023 · Direct mention

Discussion

No comments yet — be the first to weigh in on ABUS.

Sign in to join the discussion.

Scroll to Top